Taysha Gene Therapies Provides Initial Phase 1/2 Trial Clinical Data and Reports Corporate Update with Q2 Financial Results

August 14, 2023

(24/7 MARKET NEWS) – Taysha Gene Therapies, Inc. (NASDAQ:TSHA) reported, this morning, its second quarter financial results and provided data from first adult patient dosed in REVEAL Phase 1/2 trial, which showed TSHA-102 was well-tolerated with no treatment-emergent serious adverse events (SAEs) as of six-week assessment and improvement in key efficacy measures, including Clinical Global Impression – Improvement (CGI-I), Clinical Global Impression – Severity (CGI-S) and Rett Syndrome Behavior Questionnaire (RSBQ), four weeks post-treatment. Additionally, it closed a private placement financing that is expected to raise approximately $150 million, which, along with existing cash and cash equivalents, extends its cash runway into the third quarter of 2025

Taysha Gene is trading at 0.96, up $0.22 (+29.73%), on 3.51M premarket shares traded.

Its 52-week range is $0.50 to $4.63. It’s cleared several key inflection points and should try to make a run at its March and February trading levels, which includes an interesting gap to $1.50.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to 247marketnews.com or https://247marketnews.com/terms-disclaimer/ for further information.

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.